<DOC>
	<DOCNO>NCT02538627</DOCNO>
	<brief_summary>This Phase 1 open-label , dose-escalation trial use `` 3+3 '' design , evaluate MM-151 co-administration MM-121 varying dose level .</brief_summary>
	<brief_title>Phase 1 Combination Study MM-151 MM-121</brief_title>
	<detailed_description>This two-part Phase 1 , non-randomized , open-label study MM-151 plus MM-121 patient advance , heregulin-positive lung , head neck , colorectal cancer . In part 1 study cohort 3 patient treat escalate dos MM-151 combination MM-121 maximum tolerate combination dose identify . In part 2 study , patient treat combination dose identify part 1 study .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must &gt; 18 year age Patients must able provide inform consent Willing abstain sexual intercourse use effective form contraception study 90 day follow last dose study therapy ) . This apply woman childbearing potential well fertile men partner Patients must recover effect prior surgery , radiotherapy antineoplastic therapy , CTCAE grade 1 Patients must heregulinpositive cancer Patients pregnant lactate Patients active infection unexplained fever &gt; 38.5Â°C screen visit first schedule day dose ( discretion investigator , patient tumor fever may enrol . ) Patients untreated ( primary ) symptomatic CNS ( primary metastatic ) malignancy ; patient CNS metastases undergone surgery radiotherapy stable dose corticosteroid least 2 week whose disease stable prior first schedule day dose eligible trial . Patients receive recent antitumor therapy include standard chemotherapy radiation within 14 day ( passed time actual anticipated toxicity ) prior first schedule dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Heregulin-positive</keyword>
	<keyword>EGFR</keyword>
	<keyword>ErbB3</keyword>
	<keyword>Phase I</keyword>
	<keyword>Oncology</keyword>
	<keyword>Cancer</keyword>
</DOC>